本页面由Tiger Trade Technology Pte. Ltd.提供服务

IN8bio, Inc.

2.06
+0.17008.99%
盘后2.00-0.0600-2.91%16:55 EDT
成交量:9.55万
成交额:19.26万
市值:2,028.50万
市盈率:-0.46
高:2.11
开:1.89
低:1.85
收:1.89
52周最高:7.50
52周最低:1.17
股本:984.71万
流通股本:915.07万
量比:1.57
换手率:1.04%
股息:- -
股息率:- -
每股收益(TTM):-4.4441
每股收益(LYR):-4.4441
净资产收益率:-92.49%
总资产收益率:-46.64%
市净率:0.74
市盈率(LYR):-0.46

数据加载中...

公司资料

公司名字:
IN8bio, Inc.
交易所:
NASDAQ
成立时间:
2016
员工人数:
17
公司地址:
350 5th Avenue,Suite 5330,New York,New York,United States
邮编:
10118
电话:
传真:
- -
简介:
In8bio, Inc.于2016年2月8日在百慕大注册成立。该公司是一家领先的临床阶段生物制药公司,专注于癌症和自身免疫性疾病的gamma-delta T细胞治疗候选产品和gamma-delta T细胞接合剂的发现、开发和商业化。

董事

名称
职位
Alan S. Roemer
Chairman of the Board
William Ho
President,Chief Executive Officer and Director
Corinne Epperly
Independent Director
Emily T. Fairbairn
Independent Director
Jeremy Graff
Independent Director
Luba Greenwood
Independent Director
Peter Brandt
Independent Director

股东

名称
职位
William Ho
President,Chief Executive Officer and Director
Kate Rochlin
Chief Operating Officer and President
Patrick McCall
Chief Financial Officer
Lawrence Lamb
Executive Vice President, Chief Scientific Officer and Co-Founder